Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|September 5, 2019
Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemiaClaudia Lanvers-Kaminsky, Andreas Niemann, Maria Eveslage, et al.
Therapeutic Drug Monitoring|February 6, 2020
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 StudyGudrun Würthwein, Claudia Lanvers-Kaminsky, Joachim Gerss, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2002
PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocolsHans-Joachim Müller, Rita Beier, João Casimiro da Palma, et al.
Antimicrobial Agents and Chemotherapy|January 22, 2013
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosisGudrun Würthwein, Oliver A Cornely, Mirjam N Trame, et al.
Pharmacogenomics|April 1, 2015
Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicityClaudia Lanvers-Kaminsky, Jason A Sprowl, Ingrid Malath, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing DataGudrun Würthwein, Claudia Lanvers-Kaminsky, Christian Siebel, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2011
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipientsGudrun Würthwein, Charlotte Young, Claudia Lanvers-Kaminsky, et al.
Therapeutic Drug Monitoring|December 7, 2017
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 TrialClaudia Lanvers-Kaminsky, Andrea Rüffer, Gudrun Würthwein, et al.
BMC Pharmacology & Toxicology|May 30, 2020
Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedureChristian Siebel, Gudrun Würthwein, Claudia Lanvers-Kaminsky, et al.
Haematologica|December 10, 2020
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemiaAlaeddin Khalil, Gudrun Würthwein, Jana Golitsch, et al.
Pageof 10